Prevalence and Characteristics of Hepatitis Delta Virus Infection in a Tertiary Hospital Setting in Cameroon

Luma, Henry Namme; Eloumou, Servais Albert Fiacre Bagnaka; Okalla, Cécile; Donfack-Sontsa, Olivier; Koumitana, Ruth; Malongue, Agnès; Nko’Ayissi, Georges B.; Noah, Dominique Noah

doi:10.1016/j.jceh.2017.05.010

Cited by 13 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is similar to that found by Butler et al in 2018 [2] and Luma et al in 2017 [23]; this average age is the same as that found in HBV patients in Cameroon [24]. The male predominance found in this work is the same as that found by Stockdale et al in 2017 [25] in London and Luma et al in Cameroon in 2017 [23]. The risk factors found in delta virus infection are mainly male homosexuality, intravenous drug use, human immunodeficiency virus (HIV), hepatitis C virus infection and sexual intercourse with multiple partners [26,27].…”

Section: Discussionsupporting

confidence: 92%

“…The mean age in our study was 36.33 ± 10.9 years. It is similar to that found by Butler et al in 2018 [2] and Luma et al in 2017 [23]; this average age is the same as that found in HBV patients in Cameroon [24]. The male predominance found in this work is the same as that found by Stockdale et al in 2017 [25] in London and Luma et al in Cameroon in 2017 [23].…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Virological response of hepatitis Delta infection to treatment with Pegylated Interferon alpha 2a in a high prevalence country

Bagnaka

Nga²,

Kenfack³

et al. 2020

OJGH

View full text Add to dashboard Cite

Research Article OJGH (2020) 3:32 Virological response of hepatitis Delta infection to treatment with Pegylated Interferon alpha 2a in a high prevalence country The prevalence of Hepatitis Delta Virus (HDV) infection in Cameroon is 11.01%. Pegylated interferon alpha 2a (PEG-IFN α 2a) is the standard treatment worldwide. This study aimed to describe the virological response to this drug in cameroonians. Methods: We carried out a cross-sectional study from 1 January 2012 to 31 December 2018. It took place in eleven (11) health facilities of Yaoundé and Douala. Patients with HDV infection and treated with PEG INF α 2a for at least 48 weeks were included. The primary endpoint was Virologic Response (VR) and secondary endpoints were Rapid Virologic Response (RVR) and Late Virologic Response (LVR). Results: We included 133 patients. The mean age was 36.33 ± 10.9 years. The male sex accounted for 65.41% of cases. The VR was 67.67%. Leukopenia, fever, headache, asthenia and abdominal pain were the most common adverse events in 88.72%, 68.42%, 53.38%, 45.11% and 35.34% of cases respectively. Factors associated with VR were the presence of diabetes (aOR= 4.32; CI95% [1.22-15.30], p= 0.023), fever (aOR= 5.16, CI95% [1.48-18.04], p=0.01) and ALT levels greater than 40 IU/l (aOR= 3.69, IC95% [1.15-11.18], p= 0.028). Conclusion: VR is high in cameroonians. The presence of diabetes and elevated transaminases are factors associated with this virologic response. We recommend the use of interferon treatment for patients with HDV infection in Cameroon with very strict monitoring of side effects.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 92%

Virological response of hepatitis Delta infection to treatment with Pegylated Interferon alpha 2a in a high prevalence country

Bagnaka

Nga²,

Kenfack³

et al. 2020

OJGH

View full text Add to dashboard Cite

show abstract

“…In these settings, transmission of HDV through contact with the blood or other body fluids of an infected person is common ( 23 ), while the risk of vertical spread seems to be low ( 20 ). Recent data on the HDV seroprevalence among HBsAg carriers in Cameroon ranged from 11% ( 24 ) to 18% ( 25 ). HDV exhibits a high degree of genetic heterogeneity and has been classified into eight different clades (1 to 8) ( 26 ), of which clade 1 has a worldwide distribution ( 27 ).…”

Section: Introductionmentioning

confidence: 99%

Transmission of Hepatitis B and D Viruses in an African Rural Community

et al. 2018

View full text Add to dashboard Cite

This study revealed that the prevalence of HBV and HDV in a rural area of Cameroon is extremely high, underlining the pressing need for the improvement of control strategies. Systematic serological and phylogenetic analyses of HBV sequences turned out to be useful tools to identify networks of virus transmission within and between households. The high HBsAg carriage rate found among children demonstrates that implementation of the HBV birth dose vaccine and improvement of vaccine coverage will be key elements in preventing both HBV and HDV infections. In addition, the high HBsAg carriage rate in adolescents and adults emphasizes the need for identification of chronically infected individuals and linkage to WHO-recommended treatment to prevent progression to liver cirrhosis and hepatocellular carcinoma.

show abstract

“…The prevalence of anti-HDV in 258 cases of HBV-positive cases in Lebanon and Greece was 1.2% and 0.23% respectively. The prevalence of anti-HDV in HBsAg positive patients has been reported in Burkina Faso as 3.4%, in Libya as 2.5%, in California as 3.6%, and in Cameroon as 10.5% (28)(29)(30)(31). In general, studies have shown that the prevalence of HDV is declining around the world and this decline can be the result of global HBV vaccination, increased awareness, strategies for the importance of prevention and socioeconomic conditions (16).…”

Section: Discussionmentioning

confidence: 99%

The Prevalence of Hepatitis Delta Virus in Patients with Chronic Hepatitis B and Its Association with Risk Factors

Bineshian

Sharifi

2019

Middle East J Rehabil Health Stud

View full text Add to dashboard Cite

Background: Hepatitis B infection is a serious health problem and two billion people worldwide are infected with the virus. The hepatitis delta virus (HDV) is a satellite virus. Hepatitis D virus infection in HBsAg carriers can be present as a simultaneous and acute infection. Objectives: The aim of this study was to evaluate the frequency of HDV in patients with chronic hepatitis B and its association with risk factors. Methods: In this descriptive study, 74 patients with chronic HBV infection were selected from patients that had referred to the Clinical Lab of Blood Transfusion Organization. All patients were positive for HBsAg for more than six months and anti-HBc. All samples were negative for HIV and HCV. An anti-HDV test was performed on HBsAg-positive specimens by the enzyme linked immunosorbent assay (ELISA) method. Also, HBV-real-time polymerase chain reaction (PCR) testing was done to determine the viral load. Results: In this study, 74 HBsAg positive patients with a mean age of 50.22 ± 15.09 years were studied. Five (6.8%) patients had anti-HDV antibodies. Furthermore, 60% of the patients with HDV had risk factors, such as addiction, family history of hepatitis B, and a history of surgery. Maximal viral load in plasma samples of patients with anti-HDV antibodies, 531 IU/mL, was determined. Conclusions: For prevention of HDV transmission, all patients of chronic hepatitis B with low-level viral load should be evaluated for hepatitis D infection. Also, for determining the relationship between HDV infections with its risk factors, another study with a larger sample size should be performed.

show abstract

Prevalence and Characteristics of Hepatitis Delta Virus Infection in a Tertiary Hospital Setting in Cameroon

Cited by 13 publications

References 26 publications

Virological response of hepatitis Delta infection to treatment with Pegylated Interferon alpha 2a in a high prevalence country

Virological response of hepatitis Delta infection to treatment with Pegylated Interferon alpha 2a in a high prevalence country

Transmission of Hepatitis B and D Viruses in an African Rural Community

The Prevalence of Hepatitis Delta Virus in Patients with Chronic Hepatitis B and Its Association with Risk Factors

Contact Info

Product

Resources

About